Skip to main content
RCKT
NASDAQ Life Sciences

Rocket Posts $49.2M Q3 Loss, $279.4M Cash, Runway Into Q3 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$2.36
Mkt Cap
$262.361M
52W Low
$2.165
52W High
$5.45
52W Position info
9.0% above low
Off High info
57% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

RCKT is trading near its 52-week low of $2.165 (9.0% above the low).

Summary

Rocket reported a $49.2M third-quarter net loss and $279.4M in cash and investments, with runway guided into Q3 2028 after the PRV sale and first Hercules draw. Two things now drive the story: the Hercules covenants and the mid-2028 Danon topline.


Key Events · Earnings and Guidance · RCKT

  • Q3 Loss Narrowly Improves

    Net loss of $49.2M versus $50.3M in Q3 2025. R&D fell $2.9M to $31.2M on lower headcount, while G&A rose $1.4M to $19.8M on post-marketing commitments.

  • Cash of $279.4M, Runway to Q3 2028

    Cash, equivalents and investments totaled $279.4M at September 30, 2026, including the $180M PRV sale and the initial $35M Hercules draw. Management guides runway into Q3 2028, extendable into 2029 with further draws.

  • Hercules Covenants Tighten From July 2027

    The $150M facility requires qualified cash of at least 55% of outstanding debt starting July 1, 2027, falling to 45% and 35% on the Tranche 2 and approval milestones but rising to 75% if the Danon program is terminated or fails. The covenant is waived while market cap is at least $600M.

  • Securities Suit Largely Dismissed

    On October 28, 2026 the court dismissed with prejudice the claims over undisclosed Phase 2 safety events and trial design changes. The remaining dosing-progress claim and control-person claims were dismissed without prejudice.


Analysis · RCKT · Life Sciences

Operationally, the quarter was unremarkable: a $49.2M net loss versus $50.3M a year ago, with R&D down $2.9M on lower headcount. The balance sheet is what matters. Cash and investments of $279.4M, after the $180M PRV sale and the first $35M draw on the Hercules facility, fund operations into the third quarter of 2028, according to management. That removes near-term financing risk, but the Hercules terms carry a real string: from July 1, 2027 the company must hold qualified cash equal to 55% of outstanding debt, rising to 75% if the Danon program is halted or fails. Such a covenant could force a raise or a wind-down of spending precisely if the RP-A501 data disappoint. Also new: on October 28, 2026 the court dismissed with prejudice the core securities class action claims over the Phase 2 safety disclosures, leaving only a narrower dosing-progress claim alive.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RCKT was trading at $2.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $262.4M. The 52-week trading range was $2.17 to $5.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RCKT - Latest Insights

RCKT
Oct 06, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.50
Real-time Price: $2.30 info
Change: -$0.200 (-8%) info
Market Cap: $252.482M info
RCKT
Oct 06, 2026, 4:12 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $2.48
Real-time Price: $2.30 info
Change: -$0.180 (-7%) info
Market Cap: $252.482M info
RCKT
Sep 15, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.49
Real-time Price: $2.30 info
Change: -$1.19 (-34%) info
Market Cap: $252.482M info
RCKT
Sep 15, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $3.45
Real-time Price: $2.30 info
Change: -$1.15 (-33%) info
Market Cap: $252.482M info
RCKT
Aug 10, 2026, 4:00 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $3.63
Real-time Price: $2.30 info
Change: -$1.33 (-37%) info
Market Cap: $252.482M info